Peptic ulcer: General and ambulatory management;Úlcera péptica: Manejo general y extrahospitalario

Medicine

Volumn 10, Issue 3, 2008, Pages 133-140

  Sainz Samitiera R ^a   Cabrerizo Garciaa J L ^a   Cecilio Irazolaa, A ^a   Estebanc, O ^b  

^a HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^b CENTRO DE SALUD DELICIAS SUR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 42049107720     PISSN: 03045412     EISSN: 15788822     Source Type: Journal    
DOI: 10.1016/s0211-3449(08)72886-8     Document Type: Article

References (21)

1. •• Samitier R, Ponce J, Ortiz V, Piqué JM, Pérez J, Lanas A, et al. Enfermedades del estómago y del duodeno. En: Farreras P, Rozman C, editores. Medicina Interna. 15th ed. Madrid: Elsevier; 2004. p. 125-62.
2. Inadomi JM, Sonnenberg A. The impact of peptic ulcer disease and infection with Helicobacter pylori on life expectancy. Am J Gastroenterol. 1998;93(8):1286-90.
3. Martín C, Boixeda D. Úlcera péptica. En: Ponce J, editor. Tratamiento de las enfermedades gastroenterológicas. 2nd ed. Asociación Española de Gastroenterología, SCM; 2006. p. 111-21.
4. Rotter JI. Peptic ulcer. En: Emery AE, Rimoin DL, editors. The principles and practice of medical genetics. New York: Churchill Livingstone; 1983. p. 863-78.
5. Boren T, Falk P, Roth KA, Larson G, Normark S. Attachment of Helicobacter pylori to human gastric ephitelium mediated by blood group antigens. Science. 1993;262:1892-5.
6. Hein HO, Suadicani P, Gyntelberg F. Genetic markers for peptic ulcer: a study of 3,387 men aged 54 to 74 years. The Copenhagen Male Study. Scand J Gastroenterol. 1997;32:16-21.
7. The UROGAST Study Group. Epidemiology of, and risk factors for, Helicobacter pylori infection among 3,194 asymtomatic subjects in 17 populations. Gut. 1993;34:1672-6.
8. • Beswick EJ, Suárez G, Reyes VE. H. pylori and host interactions that influence pathogenesis. World J Gastroenterol. 2006;12(35): 5599-605.
9. Schoen RT, Vender RJ. Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage. Am J Med. 1989;86:449-58.
10. •• Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: A meta-analysis. Ann Intern Med. 1991;115:787-96.
11. • Lanas A, Ducóns JA, Márquez M, Martínez T, Sáinz R. Prevalencia del consumo de tabaco en pacientes con úlcera péptica en Aragón. Gastroenterol Hepatol. 1986;9:479-85.
12. • Johnston D, Martin I. (Duodenal ulcer) Treatment: surgical. En: Bouchier ID, editor. Gastroenterology: clinical science and practice. 2nd ed. London: WB Sauders; 1993. p. 290-305.
13. •• Spechler S. Úlcera péptica y sus complicaciones. En: Feldman M, Friedman L, Sleisenger M, editores. Enfermedades gastrointestinales y hepáticas. 2nd ed. Madrid: Panamericana; 2004. p. 787-817.
14. • Isenberg JI, Peterson WL, Elashoff ID, Sandersfeld MA, Reedy TJ, Ippoliti AF, et al. Healing of benign gastric ulcer with low-dose antacid of cimetidina: a doble-blind, randomized, placebo-controlled trial. N Engl J Med. 1983;308:1319-24.
15. Ables AZ, Pharm D, Simon MD. Update on Helicobacter pylori treatment. Am Fam Physician. 2007;75:351-8.
16. Qasim A, Sebastian S, Thornton O, Dobson M, McLoughlin R, Buckley M, et al. Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients. Aliment Pharmacol Ther. 2005;21:91-6.
17. Hojo M, Miwa H, Nagahara A, Sato N. Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection. Scand J Gastroenterol. 2001;36:690-700.
18. • Croom KF, Goa KL. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. Drugs. 2003; 63(24):2769-802.
19. Gisbert JP, Boixed D, Miguel D, et al. Infección por Helicobacter pylori y úlcera péptica. En: Boixeda D, Miguel D, Gisbert JP, Martín de Argila C, editores. Infección por Helicobacter pylori. ¿Dónde está el límite? Madrid: Prous Science; 1996. p. 135-57.
20. Harris P, Serrano C, Venegas A. Vacunas en desarrollo: Helicobacter pylori. Rev Chil Infect. 2006;23(3):249-56.
21. • Tarnawski A. Gene therapy for ulcerations of the gastrointestinal tract. Drugs Today. 2006;42(3):193.